Influence of prognostic factors on outcomes among metastatic breast cancer patients treated with CDK4&6 inhibitors in routine clinical practice

被引：0
|
作者：
Saverno, K. R.
Carter, G. C.
Li, L.
Battiato, L. A.
Huang, Y-J
Smyth, E. N.
Price, G. L.
Sheffield, K. M.
Baxi, S. S.
Kuk, D.
Seidman, A. D.
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Flatiron Hlth, New York, NY USA
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-P2-08-38
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-08-38
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Treatment Experiences with CDK4&6 Inhibitors Among Women with Metastatic Breast Cancer: A Qualitative Study
    Stephenson, Judith J.
    Gable, Jonathon Colby
    Zincavage, Rebekah
    Price, Gregory L.
    Churchill, Collin
    Zhu, Emily
    Stenger, Keri
    Singhal, Mukul
    Nepal, Bal
    Grabner, Michael
    Fisch, Michael J.
    Debono, David
    Geschwender, Amy R.
    Carter, Gebra Cuyun
    PATIENT PREFERENCE AND ADHERENCE, 2021, 15 : 2417 - 2429
  • [2] Clinical outcomes of CDK4/6 inhibitors in patients with bone only metastatic breast cancer
    Mardani, Mahta
    Noordeen, Suleyman
    Clifton, Katherine
    Ma, Cynthia
    Luo, Jingqin
    Xi, Jing
    Bagegni, Nusayba
    Ademuyiwa, Foluso
    Suresh, Rama
    Frith, Ashley
    Davis, Andrew
    Bose, Ron
    Peterson, Lindsay
    Thomas, Shana
    Tao, Yu
    Kobayashi, Takayuki
    Xiang, Jingyu
    Xu, Yalin
    Su, Xinming
    Weilbaecher, Katherine
    CANCER RESEARCH, 2024, 84 (09)
  • [3] Effect of timing of recurrence on outcomes in patients with metastatic breast cancer treated with CDK4/6 inhibitors
    Niraula, Sujan
    Villamarin, Diego
    Smith, Tae
    Babbra, Ramandeep
    Mahant, Akhil
    Strawderman, Myla S.
    Kharel, Zeni
    Tinkham, Christie
    Tiongson, Michael
    Bamarajpet, Nikhil
    Houshyar, Samin
    Kim, Erica
    Weiss, Anna
    Falkson, Carla Isadora
    O'Regan, Ruth
    Zhang, Huina
    Dhakal, Ajay
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] CDK4/6 inhibitors for metastatic breast cancer in routine clinical practice in Spain: survey of patterns of use and oncologists' perceptions
    Moreno, F.
    Iranzo, V.
    Alvarez, I.
    Anton, A.
    Chacon, J. I.
    Gavila, J.
    Martin, M.
    Rovira, P. Sanchez
    Gratal, P.
    Gonzalez, M. J. Fernandez
    Lopez, R.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025,
  • [5] Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer
    Hanna, Paul E.
    Strohbehn, Ian A.
    Moreno, Daiana
    Harden, Destiny
    Seethapathy, Rituvanthikaa
    Sawtell, Rani
    Wang, Qiyu
    Ouyang, Tianqi
    Katz-Agranov, Nurit
    Dinulos, James
    Wander, Seth A.
    Gupta, Shruti
    Sise, Meghan E.
    NPJ BREAST CANCER, 2023, 9 (01)
  • [6] Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer
    Paul E. Hanna
    Ian A. Strohbehn
    Daiana Moreno
    Destiny Harden
    Rituvanthikaa Seethapathy
    Rani Sawtell
    Qiyu Wang
    Tianqi Ouyang
    Nurit Katz-Agranov
    James Dinulos
    Seth A. Wander
    Shruti Gupta
    Meghan E. Sise
    npj Breast Cancer, 9
  • [7] Valuable predictive power of prognostic nutritional index in metastatic breast cancer patients treated with CDK4/6 inhibitors
    Onder, Tugba
    Oner, Irem
    Karacin, Cengiz
    Ates, Ozturk
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2025,
  • [8] The prognostic importance of glucose-to-lymphocyte ratio and uric acid in metastatic breast cancer patients treated with Cdk 4/6 inhibitors
    Yilmaz, Hatice
    Nigdelioglu, Busra
    Aytac, Ali
    Turan, Merve
    Oktay, Esin
    Yersal, Ozlem
    Barutca, Sabri
    FUTURE ONCOLOGY, 2022, 18 (27) : 3043 - 3053
  • [9] ADHERENCE TO CDK4/6 INHIBITORS AMONG PATIENTS WITH METASTATIC BREAST CANCER: A MULTILEVEL PERSPECTIVE
    O'Neill, Suzanne C.
    Pensak, Nicole Amoyal
    Vadaparampil, Susan T.
    Lynce, Filipa
    Graham, Deena M. A.
    Conley, Claire C.
    Lopez, Katherine
    ANNALS OF BEHAVIORAL MEDICINE, 2019, 53 : S276 - S276
  • [10] The prognostic indicator in breast cancer treated with CDK4/6 inhibitors: the prognostic nutritional index
    Keskinkilic, Merve
    Semiz, Huseyin Salih
    Polat, Gul
    Arayici, Mehmet Emin
    Yavuzsen, Tugba
    Oztop, Ilhan
    FUTURE ONCOLOGY, 2023, : 517 - 529
12345